Prescription Drug Costs: Can Increased Competition Restrain Prices?

During this webinar, panelists discussed the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.

Public Webinar

Electronic Materials

There has been growing momentum among policymakers to address rising prescription drug prices. One solution is leveraging market forces to bring down costs by increasing competition through generics and biosimilars. During this webinar, panelists discussed the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.

Moderator:

Mary Ella Payne, MSPH, R.N., acting president and chief executive officer, Alliance for Health Policy

Panelists:

  • Sameer Awsare, M.D., associate executive director, The Permanente Medical Group
  • Dora Hughes, M.D., senior policy advisor, Sidley Austin LLP
  • Robert Langreth, science and health reporter, Bloomberg News
*Please note a fourth speaker from a pharmaceutical company was scheduled but was unable to attend the discussion *

 

 The Alliance for Health Policy gratefully acknowledges the support of the National Institute for Health Care Management (NIHCM) for this event.